SeraCare Expands Infectious Disease Offerings with Six New Product Introductions
MILFORD, Mass., Feb. 9, 2012 /PRNewswire/ — SeraCare Life Sciences (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced today that the Company launched five new infectious disease panels and added a product line extension to its ACCURUN controls portfolio in January. These latest offerings include a performance panel for Parvovirus B19, most commonly associated with Fifth Disease, as well as new panels for HIV, Hepatitis B Virus (HBV), Hepatitis A Virus (HAV) and Cytomegalovirus (CMV) markers and positive controls to monitor molecular test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.
“Research and development, particularly in the infectious disease space, continue to advance at a rapid pace and SeraCare is committed to matching this pace with new products that meet the demands of our customers,” said Gregory A. Gould, Interim President and Chief Executive Officer and Chief Financial Officer. “The products and capabilities announced today add to SeraCare’s growing portfolio and support our leadership position as a trusted supplier of high-quality panels, controls, reagents and other critical tools for biological research.”
New product highlights:
Parvovirus B19 Mixed Titer Performance Panel (PVP201) is the world’s first commercially available performance panel for Parvovirus B19 markers with naturally occurring plasma samples. Parvovirus B19 or Fifth Disease often affects preschoolers or school-age children during the spring and leads to a rash on the cheeks, arms and legs. The panel is designed to help diagnostic manufacturers, clinical laboratories and plasma fractionators evaluate their parvovirus assays effectively.
HIV Genotype Performance Panel (PRD201) provides researchers with a diverse set of samples, including eight different HIV-1 genotypes from seven countries. This unique panel is designed to help researchers, manufacturers and labs develop, evaluate and troubleshoot a variety of HIV assays, including those for HIV RNA and the newest screening tests for combined HIV antigens and antibodies.
Worldwide HBV DNA Performance Panel (WWHD301) marks the addition of a worldwide Hepatitis B panel to SeraCare’s panel offering and includes samples from 10 countries. SeraCare delivers the broadest range of data available for a panel of this kind, with information on genotype, drug resistance mutations and test results for HBV DNA and HBV antigens.
Anti-Hepatitis A Virus Mixed Titer Performance Panel (PHT202) offers customers a 21-member panel, containing specimens collected from 2000 to 2010 and represents a diverse range of HAV reactivities. Data are available for both new and established test methods, providing greater applicability across a broad range of laboratory and research settings.
Anti-CMV (Cytomegalovirus) Mixed Titer Performance Panel (PTC203) is available exclusively from SeraCare and provides 21 naturally occurring panel members with data from twelve commercially available anti-CMV assays. Cytomegalovirus (CMV) is a common infection that is typically harmless but can cause serious disease in immunocompromised individuals and in babies infected before birth.
ACCURUN Nucleic Acid Positive Controls monitor molecular test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). With the launch of Series 100 controls, SeraCare adds support for the Gen-Probe Aptima Combo 2® Assay to complement the support already offered through Series 700 for the Becton Dickinson BD ProbeTec(TM) assay, the Becton Dickinson BD Viper(TM) and the Abbott m2000(TM) real time systems.
About SeraCare Life Sciences, Inc.
SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry. www.seracare.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. (“SeraCare” or the “Company”). For example, all statements regarding the future of our recently introduced new products and anticipated new products are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as “expect,” “believe,” “anticipate,” “intend,” or similar expressions. Actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, the risk that our new products do not produce the revenues we anticipate, the risk that sales of our new products may be slower than we expect and uncertainty regarding market acceptance of our new products. Many of these factors are beyond our ability to control or predict.
Gregory A. Gould
Interim President and Chief Executive Officer and Chief Financial Officer
SeraCare Life Sciences, Inc.
MacDougall Biomedical Communications
SOURCE SeraCare Life Sciences